Topical Tranexamic Acid in Primary Breast Augmentation Surgery: Short- and Long-term Outcomes

Area of Science:

• Plastic Surgery
• Surgical Innovation

Background:

• Breast augmentation mammaplasty (BAM) is a popular cosmetic procedure.
• Bleeding during BAM increases the risk of capsular contracture.
• Tranexamic acid (TXA) is an antifibrinolytic agent used to reduce surgical bleeding.

Purpose of the Study:

• To evaluate the efficacy and safety of topical tranexamic acid (TXA) in breast augmentation mammaplasty (BAM).

Main Methods:

• A single-surgeon case series involving 288 patients undergoing primary BAM.
• Topical TXA spray was applied to the implant pocket before prosthesis insertion.
• Postoperative complications and long-term outcomes, including capsular contracture, were monitored.

Main Results:

• The overall complication rate was 2.8% over five years.
• No instances of postoperative bleeding or hematoma were reported.
• Low rates of reoperation for rippling (1.0%), pocket revision (0.7%), capsular contracture (0.3%), and rupture (0.3%) were observed.

Conclusions:

• Topical TXA is a safe and potentially beneficial adjunct in breast augmentation mammaplasty.
• The use of TXA was associated with reduced bleeding and capsular contracture rates.
• Further research may support the routine use of TXA in BAM procedures.